Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour. 2 After activation by an antigen presenting cell, a T helper cell segregates the cytokines. Some approaches have already reached the clinical trial stage, with others not far behind.
98 
Let's personalize your content